150 related articles for article (PubMed ID: 28983943)
1. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Ranchon F; Vantard N; Henin E; Bachy E; Sarkozy C; Karlin L; Bouafia-Sauvy F; Gouraud A; Schwiertz V; Bourbon E; Baudouin A; Caffin AG; Vial T; Salles G; Rioufol C
Hematol Oncol; 2018 Apr; 36(2):399-406. PubMed ID: 28983943
[TBL] [Abstract][Full Text] [Related]
2. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
[TBL] [Abstract][Full Text] [Related]
3. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors.
Reeves DJ; Moore ES; Bascom D; Rensing B
Br J Clin Pharmacol; 2014 Sep; 78(3):565-71. PubMed ID: 24646036
[TBL] [Abstract][Full Text] [Related]
5. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors.
Santucci R; Levêque D; Lescoute A; Kemmel V; Herbrecht R
Anticancer Res; 2010 Sep; 30(9):3807-10. PubMed ID: 20944174
[TBL] [Abstract][Full Text] [Related]
6. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.
Wang X; Song Y; Wang J; He J; Liu R; Li X; Huang H; Zhang J
Int J Clin Pharm; 2020 Feb; 42(1):23-30. PubMed ID: 31916121
[TBL] [Abstract][Full Text] [Related]
7. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
[TBL] [Abstract][Full Text] [Related]
8. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin.
Boerrigter E; Crul M
Ann Pharm Fr; 2017 Sep; 75(5):344-348. PubMed ID: 28705331
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity.
Chan AJ; Rajakumar I
J Oncol Pharm Pract; 2014 Apr; 20(2):93-9. PubMed ID: 23698198
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Bain E; Birhiray RE; Reeves DJ
Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate Elimination When Coadministered With Levetiracetam.
Reeves D; DiDominick S; Finn S; Kim HJ; Shake A
Ann Pharmacother; 2016 Dec; 50(12):1016-1022. PubMed ID: 27511814
[TBL] [Abstract][Full Text] [Related]
13. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
[TBL] [Abstract][Full Text] [Related]
14. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
Cwliklińska M; Balwierz W; Nowak J; Stanuch H
Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
[TBL] [Abstract][Full Text] [Related]
16. [Proton Pump Inhibitor and High-dose Methotrexate: Two Cases Reports].
Evrard J; Farnier E; Carcel C; Lachenal F; Vial T; Pont E
Therapie; 2015; 70(6):527-35. PubMed ID: 26242498
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
19. Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors.
Hall JJ; Bolina M; Chatterley T; Jamali F
Ann Pharmacother; 2017 Feb; 51(2):163-178. PubMed ID: 27701081
[TBL] [Abstract][Full Text] [Related]
20. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
